The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to reduce complications associated with transvenous leads while preserving efficacy in terminating malignant ventricular arrhythmias. However, current evidence supporting the S-ICD is primarily derived from industry-sponsored studies and highly specialized centers. This study aims to offer a comprehensive, nationwide, real-world assessment of all patients who underwent S-ICD implantation in France. The HONEST (coHOrte fraNcaise des dEfibrillateurs Sous cuTanés) cohort is a French nationwide, single-arm, observational ongoing study that enrolled all patients who underwent implantation of an S-ICD (EMBLEM, Boston Scientific) between October 2012 (the first implantation in France) and December 2019. Clinical endpoints are centrally adjudicated. Overall, 4,924 (77% males; 49.9 years) patients, representing 98.2% of all S-ICD implantations during the study period in France, were included. The HONEST study represents the first nationwide cohort evaluating S-ICD recipients to provide contemporary, real-world data. Its goal is to identify areas for improvement and refine strategies to prevent sudden cardiac death. (S-ICD French Cohort Study [HONEST]; NCT05302115).
Background: Left bundle branch area pacing (LBBAP) has emerged as a promising alternative to conventional biventricular pacing (BIVP) for cardiac resynchronization therapy (CRT). While previous data suggest LBBAP may provide superior outcomes, existing evidence needs more data. Methods: This retrospective study included all patients who underwent de‐novo CRT at two centers in France (2022–2024). Procedural and clinical outcomes were compared between LBBAP and BIVP groups for de‐novo CRT indications, using inverse probability weighting propensity score. Results: A total of 314 patients were included (75 LBBAP, 239 BIVP). Patients receiving LBBAP were older and more likely to have atrial fibrillation. Compared to BIVP, LBBAP was associated with shorter procedure time (96 vs. 128 min; p < 0.001), narrower paced QRS (128 vs. 139 ms; p < 0.001), and lower post‐discharge device‐related complications (1% vs. 11%; HR 0.10, 95% CI 0.01–0.84; p = 0.033). At 1‐year, improvement in left ventricular ejection fraction (LVEF) was similar between groups (median ΔLVEF +15%; p = 0.438), as were hyper‐response rates (52% vs. 60%; p = 0.231). After IPW‐PS, no significant differences were observed in heart failure hospitalization (HR 0.99, 95% CI 0.40–2.64; p = 0.999), new‐onset atrial fibrillation (HR 1.69, 95% CI 0.41–6.94; p = 0.492), sustained ventricular arrhythmias (HR 1.23, 95% CI 0.15–6.49; p = 0.828), overall (HR 1.10, 95% CI 0.44–2.62; p = 0.801), and cardiovascular deaths (HR 0.92, 95% CI 0.27–2.79; p = 0.927). Conclusion: LBBAP is associated with comparable resynchronization and clinical outcomes to BIVP, with fewer late complications.
23 January 2025 in Archives of Cardiovascular Diseases
Background and Aims: Subcutaneous implantable cardioverter defibrillator (S-ICD) therapy is well-established therapy for the prevention of sudden cardiac death. Although general anesthesia (GA) was initially advocated for implantation, non-GA has emerged as a feasible alternative in clinical practice. This study evaluated the early and long-term outcomes associated with anesthetic modality during S-ICD implantation procedures. Methods: The HONEST study nationwide, single-arm, observational cohort included all patients implanted with an S-ICD (EMBLEM™, Boston Scientific) in France between 2012 and 2019. GA was characterized by controlled unconsciousness with airway management, while non-GA included all alternative techniques. Results: Among 4,924 patients, 1,041 (21.1%) underwent non-GA. The proportion of non-GA use increased from 2.5% to 26.9% between 2012 and 2019 (p<0.001). Patients implanted with non-GA modality tended to be older (51 ± 14 vs. 50 ± 15 years), had lower left ventricular ejection fraction (41±16 vs. 43±17%), and fewer secondary prevention indications (33 vs. 38%) (all p0.1). Conclusion: Anesthesia strategy used for S-ICD implantation was not associated with poorer short- or long-term clinical outcomes, supporting non–general anesthesia as a feasible alternative in appropriately selected patients.
27 May 2025 in European Heart Journal - Case Reports